Cargando…
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel and potent small-molecule inhibitor of Gal-3. A randomised, double-blind, multicentre, placebo-controlled, phase 1/2...
Autores principales: | Hirani, Nikhil, MacKinnon, Alison C., Nicol, Lisa, Ford, Paul, Schambye, Hans, Pedersen, Anders, Nilsson, Ulf J., Leffler, Hakon, Sethi, Tariq, Tantawi, Susan, Gravelle, Lise, Slack, Robert J., Mills, Ross, Karmakar, Utsa, Humphries, Duncan, Zetterberg, Fredrik, Keeling, Lucy, Paul, Lyn, Molyneaux, Philip L., Li, Feng, Funston, Wendy, Forrest, Ian A., Simpson, A. John, Gibbons, Michael A., Maher, Toby M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156151/ https://www.ncbi.nlm.nih.gov/pubmed/33214209 http://dx.doi.org/10.1183/13993003.02559-2020 |
Ejemplares similares
-
Discovery and
Optimization of the First Highly Effective
and Orally Available Galectin-3 Inhibitors for Treatment of
Fibrotic Disease
por: Zetterberg, Fredrik R., et al.
Publicado: (2022) -
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants
por: Aslanis, Vassilios, et al.
Publicado: (2023) -
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation
por: Humphries, Duncan C., et al.
Publicado: (2022) -
Extracellular and intracellular small-molecule galectin-3 inhibitors
por: Stegmayr, John, et al.
Publicado: (2019) -
Aminopyrimidine–galactose hybrids are highly selective galectin-3 inhibitors
por: Dahlqvist, Alexander, et al.
Publicado: (2019)